FDA Terminates Recall of Gas Delivery Engine Ventilator Model 16650A After Safety Review

Key Takeaways

• FDA officially terminated the recall of Gas Delivery Engine (GDE) ventilator model 16650A in June 2016
• The recall was originally initiated by the manufacturer in May 2016 due to safety concerns with the continuous ventilator system
• Terminated recall status indicates the FDA determined the safety issue was adequately addressed by the manufacturer

---

FDA Closes Safety Review on Gas Delivery Engine Ventilator Recall

The U.S. Food and Drug Administration has officially terminated a medical device recall involving the Gas Delivery Engine (GDE) model 16650A ventilator, marking the end of a safety review that began in May 2016.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Recall Details and Timeline

The manufacturer voluntarily initiated the recall on May 17, 2016, with the FDA creating the official recall record on June 13, 2016, under recall number Z-1896-2016. The affected device is a continuous ventilator designed to mechanically control or assist patient breathing by delivering predetermined respiratory support.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

What Terminated Status Means

When the FDA assigns a “terminated” status to a medical device recall, it indicates that the agency has determined the manufacturer has taken appropriate corrective actions to address the identified safety concerns. This classification suggests that the recall objectives were met and the risk to patients was adequately mitigated.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for pharmaceutical intelligence pricing, access, and launch sequencing.

Impact on Healthcare Facilities

Ventilators are critical medical devices used in hospitals, emergency departments, and intensive care units to support patients with respiratory difficulties. The Gas Delivery Engine model 16650A serves patients requiring mechanical ventilation support, making device reliability essential for patient safety.

IntelligenceStrategic Takeaways▾

FDA officially terminated the recall of Gas Delivery Engine (GDE) ventilator model 16650A in June 2016 The recall was originally initiated by the manufacturer in May 2016 due to safety concerns with the continuous ventilator system Terminated recall status indicates the FDA determined the safety issue was adequately addressed by the manufacturer

Regulatory Oversight

The FDA’s medical device recall system operates on three classification levels, with manufacturers required to report safety issues and implement corrective measures. The terminated status of this recall demonstrates the regulatory system’s effectiveness in ensuring device safety while allowing continued patient access to necessary medical equipment.

Healthcare providers who may have been affected by this recall should verify they received proper notification and implemented any required corrective actions during the active recall period.

---

Frequently Asked Questions

What does a terminated recall status mean for patients?

A terminated recall means the FDA determined the manufacturer successfully addressed the safety concerns, and the device can continue to be used safely when the corrective actions were properly implemented.

Are Gas Delivery Engine ventilators still safe to use?

Yes, with the recall terminated, these ventilators are considered safe for continued use, provided healthcare facilities implemented any required corrective measures during the active recall period.

How does the FDA monitor medical device safety after recalls?

The FDA continues post-market surveillance through adverse event reporting, routine inspections, and ongoing communication with manufacturers to ensure device safety and effectiveness.

Related coverage

• FDA investigates Salmonella in moringa leaf powder, expands recall
• Vanda tradipitant update: FDA re-review extends to Dec. 5, 2025
• $2M Gene Therapy Cures Need a Financing Model